Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
SARS-CoV-2 PLpro Inhibitor
SIMR3030 is a highly effective inhibitor of the SARS-CoV-2 PLpro enzyme, exhibiting an IC50 value of 0.0399 µg/mL. This compound demonstrates significant antiviral activity, reducing the expression levels of SARS-CoV spike, ORF1b, IFN-α, and IL-6 mRNA. Additionally, SIMR3030 has shown a favorable safety profile in murine models, making it a valuable reagent for research into COVID-19 therapeutics and fundamental coronavirus biology. -
SARS-CoV-2 3CLpro Inhibitor
D1N8 is an effective inhibitor of the SARS-CoV-2 3CLpro enzyme, demonstrating an IC50 value of 0.44 μM with a favorable CC50 greater than 20 μM. This compound is valuable for research focused on developing anti-SARS-CoV-2 agents aimed at inhibiting 3CLpro activity, contributing to the understanding of viral replication and potential therapeutic interventions. -
SARS-CoV-2 Exonuclease Inhibitor
Dexamethasone metasulfobenzoate sodium is an inhibitor of the SARS-CoV-2 exonuclease (ExoN), targeting the catalytic site to impede viral replication. This compound is valuable for research focused on SARS-CoV-2 mechanisms and can aid in the development of therapeutic strategies against COVID-19. Its specific interaction with ExoN may provide insights into viral RNA processing and fidelity. -
SARS-CoV Inhibitor
SARS-CoV-2-IN-9 is a potent inhibitor targeting the main protease of SARS-CoV-2 by binding to subsites S1 and S2. This compound demonstrates significant antiviral activity, making it a valuable tool for research in understanding and developing treatments against COVID-19. Its application extends to studies focused on inhibiting viral replication and investigating the molecular mechanisms underpinning SARS-CoV-2 pathogenesis. -
SARS-CoV-2 Replication Inhibitor
Aranotin is a potent inhibitor of SARS-CoV-2 replication, targeting the Nsp15 viral protein. This compound demonstrates strong binding affinity, making it a promising candidate for inhibiting viral replication. Aranotin is suitable for research applications focused on understanding and combating COVID-19. -
SARS-CoV-2 NSP13 Helicase Inhibitor
FWM-3 is a potent inhibitor of the SARS-CoV-2 NSP13 helicase, a critical enzyme involved in viral replication. This compound exhibits strong antiviral activity, making it a valuable tool for research focused on the mechanisms of SARS-CoV-2. Its application is particularly relevant in studies aimed at developing therapeutic strategies against COVID-19 by targeting viral helicase functions. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-7 is a reversible covalent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 1.4 µM. This compound plays a critical role in viral replication by inhibiting the protease activity, making it a valuable tool for research into antiviral strategies against COVID-19. Its application is particularly relevant in the study of SARS-CoV-2 protease mechanisms and the development of potential therapeutic agents. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-62 is a potent inhibitor of SARS-CoV-2 replication, demonstrating low cytotoxicity in cell culture models. This compound effectively inhibits viral replication in Vero E6 and Calu-3 cells, with EC50 values of 2.97 μM and 3.82 μM, respectively. It serves as a valuable tool in research aimed at understanding and combating SARS-CoV-2 infections. -
SARS-CoV-2 Inhibitor
F8-S43-S3 is a potent inhibitor of the SARS-CoV-2 main protease, demonstrating an IC50 of 9.69 μM. This compound is valuable for research applications aimed at understanding viral replication mechanisms and developing therapeutic strategies against COVID-19. Its selectivity and effectiveness make it a critical tool in the study of SARS-CoV-2's biology and in the search for antiviral agents. -
SARS-CoV-2 Nsp13 Inhibitor
MWAC-3429 is a potent inhibitor of the SARS-CoV-2 Nsp13 helicase, demonstrating robust antiviral activity against both SARS-CoV-2 and SARS-CoV-1. With EC50 values of 5.39 μM (nLuc assay) and 17.00 μM (CPE assay), MWAC-3429 exhibits low cytotoxicity in A549-hACE2 cells, with a CC50 greater than 50 μM. This compound is valuable for research into SARS-CoV infections and the mechanistic understanding of viral helicase inhibition. -
SARS-CoV Inhibitor
MI-30 is a potent inhibitor of the SARS-CoV-2 3CLpro with an IC50 of 17.2 nM, demonstrating significant efficacy in reducing viral load and lung lesions in mouse models of SARS-CoV-2 infection. This compound serves as a valuable tool in the study of coronavirus infections, facilitating research aimed at understanding viral mechanisms and the development of therapeutic strategies. -
SARS-CoV-2 Main Protease Inhibitor
SARS-CoV-2-IN-21 is a potent inhibitor of the SARS-CoV-2 main protease, exhibiting an IC50 of 5.3 μM. This compound, a penicillin sulfone benzyl C6 derivative, is instrumental in studying viral replication and pathogenesis. Its inhibitory action makes it a valuable tool for COVID-19 research and drug development. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-6 is a selective, covalent, irreversible inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of 0.18 μM. This compound specifically targets Mpro without inhibiting key human cathepsins B, F, K, and L, or caspase 3. SARS-CoV-2 Mpro-IN-6 is suitable for research applications focused on understanding COVID-19 pathogenesis and developing therapeutic strategies against SARS-CoV-2. -
SARS-CoV-2 main protease Inhibitor
VPC285785 is a potent inhibitor of the SARS-CoV-2 main protease, exhibiting an IC50 of 0.8 μM and a Kd of 2.7 μM. This compound effectively disrupts the processing of viral polyprotein precursors, which is crucial for viral replication. In studies with MHV-infected mice, VPC285785 significantly lowered viral loads in the liver, brain, and spleen. This reagent is valuable for research focused on coronavirus infections and therapeutic development. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-18 is a potent inhibitor of the SARS-CoV-2 3C-like protease, exhibiting an IC50 of 45 nM. This compound plays a crucial role in viral replication by interrupting the cleavage of polyproteins necessary for SARS-CoV-2 maturation. It is primarily utilized in research aimed at developing antiviral strategies against COVID-19 and understanding the mechanisms of viral protease function. -
SARS-CoV-2 nsp13 Inhibitor
SARS-CoV-2 nsp13-IN-5 is a selective inhibitor of the SARS-CoV-2 non-structural protein 13 (nsp13), demonstrating IC50 values of 50 μM for ssDNA-ATPase and 55 μM for ssDNA+ ATPase activities. This compound plays a critical role in antiviral research targeting the replication machinery of SARS-CoV-2. SARS-CoV-2 nsp13-IN-5 is valuable for studies aimed at developing therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-63 is a potent inhibitor of SARS-CoV-2 replication, demonstrating low cytotoxicity. It effectively inhibits viral replication in Vero E6 and Calu-3 cells, with EC50 values of 1.99 μM and 1.92 μM, respectively. This compound is ideal for research applications focused on antiviral drug development and understanding SARS-CoV-2 pathogenesis. -
SARS-CoV 3CLpro Inhibitor
JZD-07 is a potent inhibitor of the SARS-CoV-2 main protease (3CLpro), a critical enzyme for viral replication. This compound effectively disrupts the viral life cycle, making it a valuable tool for studying SARS-CoV-2 infection and developing antiviral therapies. Its application in research can provide insights into the mechanisms of viral pathogenesis and the efficacy of potential inhibitors. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-97 is a specific inhibitor targeting the SARS-CoV-2 Nsp15 endoribonuclease, demonstrating an IC50 of 53.5 μM. This compound shows low cytotoxicity in A549-AT cells, with an IC50 of 134 μM, making it a valuable tool for studying SARS-CoV-2 biology and antiviral strategies. Its selective inhibition could aid in the development of therapeutic approaches against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-51 is an effective inhibitor targeting the fusion mechanism of the SARS-CoV-2 virus, particularly against the Omicron variant. This compound exhibits potent antiviral activity, inhibiting viral entry with EC50 values ranging from 0.82 to 5.45 μM. By directly interacting with the spike protein in its prefusion conformation, SARS-CoV-2-IN-51 serves as a valuable tool for research applications focused on COVID-19 therapeutic development and understanding viral entry mechanisms. -
SARS-CoV-2 NPro Inhibitor
SARS-CoV-2-IN-16 is a potent inhibitor of the SARS-CoV-2 nucleocapsid protein (NPro), demonstrating significant antiviral activity with an EC50 of 3.69 μM. This compound binds to NPro with a low KD value of 7.82 μM, indicating its efficacy as a high-affinity ligand. SARS-CoV-2-IN-16 is suitable for research applications focused on viral infection mechanisms and the development of therapeutic strategies against SARS-CoV-2. -
SARS-CoV-2 Inhibitor
SARS-CoV-2 3CLpro-IN-14 is an orally active inhibitor of the SARS-CoV-2 3CL protease (3CLpro), a crucial target for antiviral therapy. This compound exhibits robust anti-SARS-CoV-2 activity with an EC50 value of 0.18 μM while displaying low cytotoxicity with a CC50 greater than 50 μM in Vero E6 cells. It is applicable in the research of COVID-19 therapies, particularly for understanding viral replication mechanisms and testing potential antiviral compounds. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-19 is a potent inhibitor of SARS-CoV-2, specifically targeting the viral helicase nsp13 with an EC50 of 8.8 μM. This compound demonstrates strong anti-SARS-CoV-2 activity, making it a valuable tool for studying COVID-19 and other human coronavirus outbreaks. Its mechanism suggests applications in infectious disease research, particularly in the development of antiviral therapeutics. -
SARS-CoV Inhibitor
SARS-CoV-2-IN-99 is a potent inhibitor of the SARS-CoV-2 main protease, an essential enzyme for viral replication. This compound demonstrates significant antiviral activity, making it a valuable tool for research in the field of COVID-19 therapeutics. SARS-CoV-2-IN-99 can aid in studies aimed at developing effective antiviral strategies against SARS-CoV-2 and related coronaviruses. -
SARS-CoV-2 Inhibitor
N-0920 is a highly potent TMPRSS2 inhibitor, exhibiting an IC50 of 0.35 nM. This compound effectively inhibits the entry of SARS-CoV-2 variants EG.5.1 and JN.1 in Calu-3 cells, demonstrating remarkable picomolar EC50 values of 300 pM and 90 pM, respectively. N-0920 is an essential tool for research into viral entry mechanisms and therapeutic strategies against SARS-CoV-2. -
SARS-CoV Inhibitor
PLpro-IN-7 is a potent inhibitor of the papain-like protease (PLpro) of SARS-CoV, demonstrating an IC50 of 3 nM. This compound exhibits significant antiviral activity, making it a valuable tool in the study of SARS-CoV replication and pathogenesis. PLpro-IN-7 is essential for research focusing on the development of therapeutics targeting coronavirus infections. -
SARS-CoV-2 Inhibitor
3-Deazaguanosine is an antiviral compound targeting SARS-CoV-2, exhibiting a potent inhibitory effect with an EC50 value of 1.14 μM and a high CC50 exceeding 200 μM in Vero E6 cells. This reagent demonstrates significant potential in mitigating the severity of COVID-19 pneumonia, making it a valuable tool for research in viral pathogenesis and therapeutic development against coronavirus infections. -
SARS-CoV-2 Mpro Inhibitor
BFC204 is an inhibitor of the SARS-CoV-2 main protease (Mpro) that demonstrates a kinact/Ki value of 619 mol/s. This compound effectively disrupts the enzymatic activity of Mpro, which is essential for the viral replication process. BFC204 is utilized in research focused on antiviral drug development and the molecular mechanisms of SARS-CoV-2 pathogenesis. -
SARS-CoV-2 Viral Propagation Inhibitor
Covidcil-19 is a potent inhibitor targeting the frameshifting element (FSE) of SARS-CoV-2. By binding to the revised attenuator hairpin structure with a dissociation constant (Kd) of 11 nM, Covidcil-19 stabilizes its folded conformation, thereby impairing frameshifting efficiency. Importantly, it does not alter the RNA levels of the SARS-CoV-2 FSE. This compound serves as a valuable tool for investigating viral propagation mechanisms and presents potential applications in antiviral research against SARS-CoV-2. -
SARS-CoV-2 Mac1 Inhibitor
MDOLL-0229 is an antiviral reagent that targets the SARS-CoV-2 Mac1 protein, effectively repressing coronavirus replication. This compound demonstrates inhibitory activity against SARS-CoV-2 Mac1 with an IC50 value of 2.1 µM. MDOLL-0229 serves as a valuable tool for research applications focused on understanding SARS-CoV-2 pathogenesis and the development of antiviral strategies. -
SARS-CoV-2 Inhibitor
TKB272 is a selective antiviral agent targeting the main protease (Mpro) of SARS-CoV-2. It effectively inhibits the infection and replication of various SARS-CoV-2 strains, including Omicron variants, with an IC50 of 0.7 µM and an EC50 as low as 2.6 nM in cellular assays. Additionally, TKB272 demonstrates a high safety profile with a CC50 of 98 µM, indicating minimal cytotoxicity. Its ability to significantly reduce replication in transgenic mouse models highlights its potential as a valuable tool for SARS-CoV-2 research. -
SARS-CoV-2 E Protein Inhibitor
SARS-CoV-2-IN-117 is a potent inhibitor of the SARS-CoV-2 E protein, targeting its interaction with the host ZO-1 PDZ2 domain. This compound exhibits significant antiviral activity, effectively reducing viral replication. SARS-CoV-2-IN-117 is suitable for research applications focused on understanding and mitigating COVID-19. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-14 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro) with an IC50 of 0.044 μM. This compound demonstrates excellent water solubility and exhibits no cytotoxic effects, making it suitable for in vitro studies. SARS-CoV-2 Mpro-IN-14 is valuable for research applications focusing on COVID-19 and the development of antiviral therapeutics. -
SARS-CoV-2 main protease (Mpro) Inhibitor
UAWJ246 is a covalent reversible inhibitor targeting the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of 0.045 μM and a Ki of 0.036 μM. This compound demonstrates significant antiviral activity by effectively inhibiting SARS-CoV-2 viral replication while maintaining low cytotoxicity. UAWJ246 is suitable for research focused on SARS-CoV-2 infection and the development of therapeutic strategies for COVID-19. -
SARS-CoV Inhibitor
SARS-CoV-2-IN-82 is a selective inhibitor targeting the programmed -1 ribosomal frameshift (PRF) mechanism in SARS-CoV-2. This compound effectively disrupts viral protein translation, thereby hindering the replication of the virus. It is primarily utilized in research applications focused on understanding the mechanisms of SARS-CoV-2 infection and developing antiviral strategies. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-89 is a potent inhibitor targeting SARS-CoV-2. This compound enhances interferon type I (IFN-I) responses in A549.hACE2 cells upon viral infection, making it a valuable tool for studying antiviral mechanisms and developing therapeutic strategies against COVID-19. Its application in research facilitates a deeper understanding of the immune response to SARS-CoV-2. -
SARS-CoV-2 Inhibitor
PB49673382 is a potent inhibitor of SARS-CoV-2, demonstrating significant antiviral activity. It effectively inhibits viral replication and mitigates the cytopathic effects associated with the virus, with an IC50 value of 6.42 μM. This compound is useful for research applications focused on understanding SARS-CoV-2 biology and developing therapeutic strategies against COVID-19. -
SARS-CoV-2 3CLpro Inhibitor
DB12055 is a covalent inhibitor targeting the 3CL protease of SARS-CoV-2. It demonstrates significant inhibitory activity against this viral protease, making it a valuable tool for research focused on COVID-19. Additionally, DB12055 may be useful for investigating metabolic disorders such as dyslipidemia and diabetes mellitus. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-30 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), with an IC50 value of 9.1 nM. This compound is critical for the study of SARS-CoV-2 biology and can be utilized in research focused on antiviral drug discovery and development. Its efficacy in inhibiting viral replication makes it a valuable tool for investigating therapeutic strategies against COVID-19. -
SARS-CoV-2 Mpro Inhibitor
BFC220 is a covalent inhibitor of SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of 2.77 μM. This compound is valuable for antiviral research, specifically in studies involving the inhibition of viral protease activity and the development of targeted therapies against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-52 is a potent inhibitor targeting the SARS-CoV-2 virus, exhibiting an inhibitory potency characterized by a pIC50 of 0.3187. This compound demonstrates significant antiviral activity and is suitable for research applications aimed at understanding and mitigating SARS-CoV-2 infections. Its mechanisms may provide valuable insights into therapeutic strategies against COVID-19. -
SARS-CoV-2 Nsp12 Inhibitor
Nsp12-IN-2 is a SARS-CoV-2 Nsp12 inhibitor, specifically targeting the RNA-dependent RNA polymerase (RdRp) activity of the Nsp12-Nsp7-Nsp8 complex. This compound terminates RNA synthesis and inhibits the RNAylation and NMPylation of Nsp9. Nsp12-IN-2 shows potential for research into SARS-CoV-2 infections, as well as studies involving other coronaviruses and RNA viruses. -
SARS-CoV Inhibitor
SARS-CoV-2 Mpro-IN-51 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro) with an IC50 of 26 nM. This compound effectively targets the triple mutant variant L50F/E166A/L167F, making it a valuable tool for research into viral pathogenesis and therapeutic interventions. Its application extends to studies aimed at elucidating mechanisms of viral infection and drug resistance in SARS-CoV-2. -
SARS-CoV-2 3CL Protease Inhibitor
SARS-CoV-2 3CLpro-IN-33 is a potent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 1.5 nM. This compound demonstrates strong antiviral activity against SARS-CoV-2 in HEK293T-AT cells, with an EC50 of 0.017 μM. SARS-CoV-2 3CLpro-IN-33 is suitable for research applications focused on understanding COVID-19 infection and developing therapeutic strategies. -
SARS-CoV-2 Inhibitor
SARS-CoV-2 PLpro-IN-1 is a non-covalent, competitive inhibitor specifically targeting the SARS-CoV-2 PLpro enzyme. It demonstrates significant biological activity with an IC50 of 15.06 μM and a Ki value of 22.93 μM. Furthermore, SARS-CoV-2 PLpro-IN-1 effectively inhibits the proliferation of Vero cells, exhibiting an IC50 of 7.47 μM. This compound is suitable for research applications focused on viral inhibition and understanding the mechanisms of SARS-CoV-2 replication. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-67 is a vitamin K derivative that serves as an inhibitor of SARS-CoV-2. It exhibits significant antiviral activity against SARS-CoV-2, with an EC50 of 64.8 μM in VeroE6/TMPRSS2 cells. This compound specifically targets and inhibits the activity of SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), making it a valuable reagent for research applications in virology and the study of coronavirus infections. -
SARS-CoV-2 Inhibitor
Jobosic acid is a saturated fatty acid that functions as a selective inhibitor of SARS-CoV-2. It effectively inhibits the main protease (Mpro) and the spike receptor binding domain (RBD) interaction with ACE-2, demonstrating IC50 values of 7.5 μg/mL and 3 μg/mL, respectively. Jobosic acid also exhibits inhibitory effects on viral entry for the omicron variant of SARS-CoV-2, making it a valuable compound for research in antiviral therapies. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-69 is a non-covalent inhibitor specifically targeting the SARS-CoV-2 main protease (Mpro) with an EC50 value of 7.4 μM. This compound demonstrates potent inhibitory activity against Mpro and also acts as a non-covalent inhibitor of papain-like protease (PLpro). It is suitable for studies aimed at understanding the mechanisms of SARS-CoV-2 replication and for the development of antiviral therapeutics. -
SARS-CoV-2 Mac1-ADP-ribose Inhibitor
F594-1001 is a selective inhibitor of the SARS-CoV-2 Mac1-ADP-ribose activity, demonstrating IC50 values of 8.5 μM, 68 μM, and 45 μM in AS, FP, and FRET assays, respectively. This compound directly interacts with the Mac1 enzyme, resulting in dose-dependent inhibition of ADP-ribosylhydrolase activity. F594-1001 is valuable for research focused on understanding SARS-CoV-2 biology and developing therapeutic strategies against COVID-19. -
SARS-CoV-2-specific Entry Inhibitor
SARS-CoV-2-IN-120 is a specific entry inhibitor targeting the SARS-CoV-2 spike protein. By binding to and trimerizing within the apex cavity of the spike trimer, it effectively blocks the interaction between the receptor-binding domain (RBD) and ACE2. This compound demonstrates potent neutralization against the BA.2 lineage and subsequent Omicron variants, and has shown capabilities in inhibiting SARS-CoV-2 replication in murine models. SARS-CoV-2-IN-120 is valuable for research applications focused on viral entry mechanisms and therapeutic development against COVID-19.
